MoonLake Immunotherapeutics
MLTX
173 hedge funds and large institutions have $1.43B invested in MoonLake Immunotherapeutics in 2026 Q2 according to their latest regulatory filings, with 44 funds opening new positions, 72 increasing their positions, 44 reducing their positions, and 15 closing their positions.
198% more call options, than puts
Call options by funds: $33.5M | Put options by funds: $11.2M
193% more first-time investments, than exits
New positions opened: 44 | Existing positions closed: 15
64% more repeat investments, than reductions
Existing positions increased: 72 | Existing positions reduced: 44
22% more capital invested
Capital invested by funds: $1.17B → $1.43B (+$253M)
18% more funds holding
Funds holding: 147 → 173 (+26)
11.59% more ownership
Funds ownership: 87.9% → 99.49% (+12%)
0% more funds holding in top 10
Funds holding in top 10: 3 → 3 (0)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
T. Rowe Price Investment Management
Baltimore,
Maryland
|
+$77.6M |
| 2 |
LGM
Logos Global Management
San Francisco,
California
|
+$21.3M |
| 3 |
D.E. Shaw & Co
New York
|
+$17.7M |
| 4 |
WAM
Weiss Asset Management
Boston,
Massachusetts
|
+$15.8M |
| 5 |
TECP
Trails Edge Capital Partners
Atlanta,
Georgia
|
+$13.6M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
CAM
Cormorant Asset Management
Boston,
Massachusetts
|
-$23.1M |
| 2 |
Goldman Sachs
New York
|
-$18.1M |
| 3 |
JFG
Jefferies Financial Group
New York
|
-$9.32M |
| 4 |
CC
Casdin Capital
New York
|
-$8.39M |
| 5 |
ACM
ADAR1 Capital Management
Austin,
Texas
|
-$7.8M |
MLTX Hedge Fund Activity: Q2 2026 in Review
173 of the 8,318 institutional investors tracked by Wall St. Rank reported a position in MoonLake Immunotherapeutics (MLTX) for Q2 2026, worth a combined $1.43B — up 22% from $1.17B a quarter earlier.
Buyers outnumbered sellers: 44 funds opened new MLTX positions and 15 closed out — a net gain of 29 holders — while 72 added to existing stakes and 44 trimmed.
The largest buyer was T. Rowe Price Investment Management, opening a new position worth an estimated $77.6M. The largest seller was Cormorant Asset Management, cutting an estimated $23.1M.
- 173 institutional investors held MoonLake Immunotherapeutics (MLTX) as of Q2 2026, up from 147 in Q1 2026.
- Funds reported $1.43B of MoonLake Immunotherapeutics stock for Q2 2026, up 22% quarter-over-quarter.
- 44 funds opened new MoonLake Immunotherapeutics positions in Q2 2026 and 15 closed out, a net change of +29 holders.
- The largest MoonLake Immunotherapeutics buyer in Q2 2026 was T. Rowe Price Investment Management, an estimated $77.6M added.
- The largest MoonLake Immunotherapeutics seller in Q2 2026 was Cormorant Asset Management, an estimated $23.1M sold.
Based on aggregated 13F filings for Q2 2026.